Akili Labs and BGI Genomics Sign Agreement to Provide Southern Africa with Clinical-Grade Sequencing Solutions

Akili Labs (Pty) Ltd, a pioneer of cost-effective molecular diagnostics and secure genomic data storage solutions, and BGI Genomics Co. Ltd, the world's leading integrated solutions provider of precision medicine, today announced the signing of a technology transfer agreement that will provide the Southern region of Africa with clinical-grade sequencing solutions.

"Improving the cost and turnaround time of genetic sequencing services will play a major role in the expansion of precision medicine-driven healthcare in Africa," said Charles F.J. Faul, co-founder and Chief Executive Officer of Akili. "Locally provided services have struggled with capacity restraints and are challenged with local pricing of reagents and equipment. Often, the only solution is to send samples to Europe or the USA, where sequencing is cheaper. However, this comes at a price: the application for export permits can be a lengthy process, and then there is the risk of sample loss or damage during shipping.

Access to sequencing is only one part of the equation. This partnership supplies the first truly Africa-based service to meet our client needs. With this partnership, we can process samples locally in full compliance with regional data protection laws."

Stuart A. Ali, PhD, Chief Scientific Officer at Akili

"We are thrilled to see the progress being made in genomics sequencing development in Africa.", said Ronnie Mao, Business Manager of Southern Africa, BGI Genomics. "With the continent being home to the world's most diverse genomics data, it's crucial that local talent has the tools and resources to further our understanding of clinical genetics, we welcome the initiative to develop localized genomics sequencing capabilities in Africa, with a focus on clinical genetics and improving health outcomes. This will not only benefit the people of Africa but also it's important to enable and empower local talent to lead this effort and bring their unique perspectives to the field. We look forward to seeing the positive impact that this development will have on the health of individuals and communities in Africa."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Early T Cell Changes in Cancer Immunotherapy Patients Tied to Severe Immune Side Effects